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Chlorin e6 mediated photodynamic 
inactivation for multidrug resistant 
Pseudomonas aeruginosa keratitis 
in mice in vivo
Ming-Feng Wu1,2, Mona Deichelbohrer3, Thomas Tschernig3, Matthias W. Laschke4, 
Nóra Szentmáry1,5, Dirk Hüttenberger6, Hans-Jochen Foth7, Berthold Seitz1 & 
Markus Bischoff8
Following corneal epithelium scratches, mouse corneas were infected with the multidrug resistant 
(MDR) P. aeruginosa strain PA54. 24 hours later, 0% (for control group), 0.01%, 0.05% or 0.1% Chlorin 
e6 (Ce6), a second generation photosensitizer derived from chlorophyll, was combined with red 
light, for photodynamic inactivation (PDI). 1 hour or 2 days later, entire mouse eyes were enucleated 
and homogenized for counting colony forming units (CFU) of P. aeruginosa. For comparison, 0.1% 
Ce6 mediated PDI was started at 12 hours post infection, and 0.005% methylene blue mediated PDI 
24 hours post infection. Clinical scores of corneal manifestation were recorded daily. Compared to the 
control, CFU 1 hour after PDI started 24 hours post infection in the 0.01% Ce6 and 0.05% Ce6 groups 
were significantly lower (more than one log10 reduction), the CFU 2 days post PDI higher in the 0.1% Ce6 
group, clinical score lower in the 0.1% Ce6 group at 1 day post PDI. These findings suggest that PDI with 
Ce6 and red light has a transient efficacy in killing MDR-PA in vivo, and repetitive PDI treatments are 
required to fully resolve the infection. Before its clinical application, the paradoxical bacterial regrowth 
post PDI has to be further studied.
Pseudomonas aeruginosa (P. aeruginosa), a Gram-negative rod-shaped bacterium, is among the most common 
pathogens of bacterial keratitis1. P. aeruginosa keratitis usually causes a rapidly progressive, suppurative corneal 
infiltration, ulceration, and finally perforation and blindness2. Infections caused by P. aeruginosa are further com-
plicated by the fact that multidrug resistant (MDR) variants of this species are on the rise worldwide3,4, which are 
difficult to treat by conventional therapy, the empirical but intensive topical treatment with commonly used oph-
thalmic antibiotics, such as the fluoroquinolones ciprofloxacin and ofloxacin, the aminoglycosides gentamicin 
and tobramycin, and the 1st generation cephalosporin cefazolin, respectively5,6. Many risk factors, such as contact 
lens use, compromised ocular surface and preservative-free lubricant ointment use, can predispose patients to 
P. aeruginosa keratitis7. P. aeruginosa may also cause keratitis after keratoplasty, which often leads to a very poor 
outcome8. The development of alternative therapy options to fight this type of infection has become imperative.
Photodynamic inactivation (PDI) is a novel promising antimicrobial strategy against MDR bacteria9,10. It is a 
photochemical reaction combining light, a photosensitizer, and oxygen to generate reactive oxygen species (ROS), 
such as singlet oxygen (1O2) and hydroxyl radicals (HO)11. Unlike antibiotics, PDI causes a non-specific bacteri-
cidal effect, since ROS can damage various vital bacterial structures, mainly cell wall proteins and membranes12,13.
PDI might be especially applicable for the treatment of infectious keratitis, since the transparency and super-
ficial location of the cornea facilitate the deposition of the photosensitizer and the irradiation process. As early 
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as in the 1970s, some clinical studies already tried to treat viral keratitis with PDI, but these investigations were 
soon suspended due to severe adverse reactions, such as phototoxic epithelial keratitis and anterior uveitis14,15. 
In the following decades, only in vitro studies that explored the possibility of PDI to combat clinically important 
corneal pathogens were reported16–22. To date, the in vivo use of PDI as antimicrobial therapy is mainly restricted 
to the treatment of dermatological and dental infections23. In ophthalmology, PDI was rarely used as a treatment 
option for ocular infections, although another photodynamic therapy procedure, i.e. corneal crosslinking with 
riboflavin and ultraviolet light, is nowadays commonly applied as a treatment for corneal ectatic diseases24. A 
small number of clinical case reports indeed suggest that corneal crosslinking might be used as a therapy option 
for bacterial keratitis25–28, while other case reports indicated an increase in microbial infections as a complica-
tion of this therapy form when treating corneal ectatic diseases29–38. To date, only little experimental evidence is 
provided, whether PDI is a useful option to fight bacterial keratitis. In 2011, Shih et al.39 demonstrated the bac-
tericidal efficiency of a combination of the antibiotic amikacin and PDI with the photosensitizer methylene blue 
(MB) and red light (λ = 650 nm) in a rabbit model of Mycobacterium fortuitum keratitis. However, they did not 
assess the impact of PDI as a single treatment. In the same year, El-Laithy et al.40 treated Staphylococcus aureus 
keratitis in rabbits with the photosensitizer hematoporphyrin and red light (λ = 630 nm). However, they failed to 
detect a statistically significant impact of this therapy regimen.
In the present study, we evaluated the efficiency of PDI with the photosensitizer Ce6 and red light (λ = 670 nm) 
as a single therapy option for the treatment of MDR P. aeruginosa keratitis in mice. Previous in vitro studies 
demonstrated that this photosensitizer/light combination can kill up to 100% of the challenged P. aeruginosa 
cells41–44. However, whether such a remarkable bactericidal rate can be achieved in vivo is questionable. Under in 
vitro conditions, bacteria can be fully mixed with the photosensitizer, and the generated ROS will predominantly 
damage the bacterial cell components. The in vivo environment is much more complicated. Corneal epithelium 
and stroma may hinder the diffusion of the photosensitizer towards the bacteria within the infected tissue. ROS 
can diffuse for only short distance, e.g. less than 50 nm, once they are generated from the activated photosensi-
tizer45. Thus, a substantial proportion of ROS produced by PDI is likely to react with host components, including 
cellular structures and molecules, and may cause unexpected cascade reactions46.
To assess the effect of Ce6 mediated PDI as a single therapy for the treatment of MDR-PA keratitis in mice in 
vivo, three regimens of PDI were tested (Fig. 1). In all regimen, visible red light (λ = 670 nm) was applied, thereby 
avoiding the potential genotoxicity induced by ultraviolet light used in corneal crosslinking47.
In regimen I, at 24 h post MDR-PA infection, corneal epithelia were removed from infected mouse eyes using 
a hockey epithelium removal knife to improve the diffusion of the photosensitizer into the stroma48, before PDI 
mediated by 0%, 0.01%, 0.05%, and 0.1% (w/v) Ce6 and red light was applied. Mice were euthanized either 1 h 
post PDI or 48 h post PDI, the infected eyes enucleated and subsequently homogenized with a manual disperser 
for CFU determinations as outlined in Material and Methods.
In regimen II, PDI mediated by 0% and 0.1% Ce6 was carried out 12 h post infection on deepithelialized cor-
neas, and mice were euthanized 60 h post PDI for CFU counting. Inflammatory cells, such as neutrophils, which 
are recruited to the cornea due to the P. aeruginosa infection, are essential for controlling the bacterial population. 
However, an excessive influx and persistence of these inflammatory cells may also lead to corneal destruction2. 
PDI may interfere with the corneal response to P. aeruginosa unintentionally by killing these inflammatory cells. 
Of note, Tanaka et al.49 reported that a MB concentration of around 100 μ M, when activated with a red light dose 
of 20 J/cm2, spared neutrophils but killed most of the bacteria under in vitro conditions.
Therefore, in regimen III, we used MB as a reference to investigate whether it causes a similar effect as Ce6. 
PDI mediated by 0.005% MB was carried out at 24 h post infection. Mice were euthanized 48 h post PDI for CFU 
counting.
Figure 1. Schematic representation of key events applied in regimens I to III. Black arrows, tissue injury 
and infection; gray arrows, epithelium removal and PDI; red arrows, euthanasia, enucleation and CFU 
determinations. In regimen I, mice were either euthanized at 1 h post PDI (a) or 48 h post PDI (b).
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Results
Regimen I (Ce6 mediated PDI at 24 h post infection). In the first regimen, PA54 infected eyes were 
treated 24 h post infection by PDI with different concentrations of Ce6 and red light, and bacterial loads were 
subsequently determined in homogenates of whole eyes enucleated 1 h and 48 h post PDI treatment, respectively, 
in order to determine the short term and long term effects of PDI on the bacterial loads in the infected eyes 
(Fig. 2). The CFU values found in the eyes of PA54 infected mice 1 h after PDI are shown in Fig. 2A. Upon PDI the 
bacterial loads found in mice treated with the 0.01% Ce6 gel (Log10CFU = 5.19 ± 0.75, P = 0.028) and the 0.05% 
Ce6 gel (Log10CFU = 5.13 ± 0.61, P = 0.015) decreased significantly when compared to the CFU rates found in 
the eyes of control mice (Log10CFU = 6.21 ± 0.91) treated with the gel-base (0% Ce6) only. CFU of 0.1% Ce6 gel 
treated mice (Log10CFU = 5.41 ± 0.63) were likewise lower than the CFU of sham treated controls (i.e. 0% Ce6), 
however, this difference was not statistically significant (P = 0.058).
A different picture emerged when the bacterial loads of PA54 infected mice were determined 48 h post PDI 
(Fig. 2B). Here, the bacterial loads in the eyes of mice treated with the 0.1% Ce6 gel (Log10CFU = 7.38 ± 0.22) 
increased significantly when compared with the CFU rates found in the eyes of the sham treated control group 
(Log10CFU = 6.95 ± 0.25, P = 0.011). Likewise, CFU rates found in the eyes of the 0.05% Ce6 gel treated group 
(Log10CFU = 7.19 ± 0.13), and the 0.01% Ce6 gel treated group (Log10CFU = 7.11 ± 0.27) exceeded the CFU 
values observed in the eyes of the sham-treated control group, however, this was not statistically significant 
(P = 0.068 and 0.333, respectively).
The course of infection in the eyes of mice challenged with PA54 was additionally monitored by 
stereo-microscopic determinations and graded as outlined in Materials and Methods. The clinical scores from 
PA54 infected eyes determined 24 h, 48 h, and 72 h post infection, respectively, are shown in Fig. 3, and represent-
ative stereo-microscopic images of PA54 infected eyes over time are given in Fig. 4. Here, significant increases 
in infection severity were observed for the sham treated group and the 0.01% Ce6 group, when the development 
of infection symptoms over time within a treatment group were compared. The clinical scores of 0.01% Ce6 gel 
Figure 2. (A) Log10CFU 1 h after regimen I (chlorin e6 mediated PDI at 24 h post infection), (B) Log10CFU on 
day 3, of each mouse is displayed as a single dot in the scatter plot, grouped by the concentrations of chlorin e6 
(Ce6) used in PDI at hour 24. Mean of Log10CFU of each group is shown as a bar. (A) Log10CFU in 0.01% Ce6 
group (*P = 0.028) and 0.05% Ce6 group (*P = 0.015) are significantly lower than the control group treated 
by 0% Ce6. (B) Log10CFU in 0.1% Ce6 group is significantly higher than the control group treated by 0% Ce6 
(*P = 0.011).
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treated mice increased significantly throughout the observation period (P = 0.026 for 24 h vs. 48 h, and P = 0.026 
for 24 h vs. 72 h). Similarly, the clinical scores of sham treated mice increased significantly from 24 to 72 h post 
infection (P = 0.009). However, such increases in severity of infection over time were neither seen in 0.05% Ce6 
nor in 0.1% Ce6 treated mice.
When the clinical scores for a given time point were compared between groups, in most cases no clear dif-
ferences in infection symptoms were observed (P ≥ 0.209). The only exception was seen in the 0.1% Ce6 group, 
in which clinical scores at 48 h post infection (clinical score = 2.3 ± 0.5) were significantly lower than those seen 
with the sham treated control group (clinical score = 3.5 ± 0.5, P = 0.015). At 72 h post infection (i.e. 48 h post 
PDI), clinical scores of the 0.1% Ce6 group also displayed lower values (clinical score = 2.8 ± 0.8) than those seen 
in the control group (clinical score = 3.8 ± 0.4), although this was not statistically significant (P = 0.060).
Regimen II (chlorin e6 mediated PDI at hour 12 post infection). In the second regimen, PA54 
infected eyes were treated 12 h post infection by PDI with 0.1% Ce6 and red light, and bacterial loads were sub-
sequently determined in homogenates of whole eyes enucleated 60 h post PDI treatment (Fig. 5). This regimen 
was chosen in order to determine whether an earlier PDI treatment time point might prevent an overgrowth of 
surviving bacteria that was seen at 72 h post infection in regimen I. Interestingly, when PDI with 0.1% Ce6 and 
red light was applied earlier in infection (i.e. at 12 h post infection), the CFU values observed in the eyes of mice 
that were treated with 0.1% Ce6 (Log10CFU = 7.20 ± 0.16) were no longer different from those seen in mice of the 
sham treated control group (Log10CFU = 6.65 ± 0.67, P = 0.101). Similarly, the clinical scores observed 72 h post 
infection in mice treated by PDI with 0.1% Ce6 and red light (clinical score = 3.7 ± 0.5) were not significantly dif-
ferent from those seen in the sham treated control group (clinical score = 4.0 ± 0.0, P = 0.394) (Fig. 6). Moreover, 
clinical scores increased significantly from hour 12 to day 2 (P = 0.002), and from hour 12 to day 3 (P = 0.002) in 
both groups, when the development of infection symptoms over time within a treatment group were compared. 
Representative corneal manifestations of mice are shown in Fig. 7.
Regimen III (methylene blue mediated PDI at 24 h post infection). The photosensitizer MB is 
known to kill P. aeruginosa in vitro upon activation by red light at concentrations of about 100 μ M (equivalent 
to 0.003%), while immune cells are largely spared by this treatment49. To test whether the increased outgrowth 
of PA54 seen in the eyes of mice treated with the 0.1% Ce6 gel at hour 72 post infection (Fig. 2B) might have 
been caused by an increased impairment of immune cells, we next tested the impact of PDI by MB and red light 
(λ = 670 nm) at 24 h post infection to eradicate this pathogen in vivo in our infective keratitis model. To this end, 
only the bacterial loads 48 h post PDI were determined (Fig. 8). PDI by 0.005% MB and red light applied 24 h 
post infection yielded in CFU values (Log10CFU = 7.25 ± 0.28) that were largely comparable to those seen in 
the control group (Log10CFU = 6.98 ± 0.15, P = 0.060). Likewise, the clinical scores observed 48 h and 72 h post 
infection in mice treated by PDI with 0.005% MB and red light (clinical scores = 3.8 ± 0.4 and 3.7 ± 0.5 for 48 and 
72 h post infection) were not significantly different from those seen in the sham treated control group (clinical 
scores = 3.7 ± 0.5 and 4.0 ± 0.0 for 48 and 72 h post infection, P > 0.394) (Fig. 9). However, when the development 
of infection symptoms over time within a treatment group were compared, clinical scores of the sham treated 
control group increased significantly from hour 24 to day 3 (P = 0.002), while clinical scores of the 0.005% MB 
group increased significantly from hour 24 to day 2 (P = 0.041). Representative corneal manifestations of mice 
are shown in Fig. 10.
Discussion
Our current study assessed the effectivity of corneal PDI by the photosensitizer Ce6 and red light (λ = 670 nm) 
against MDR-PA keratitis in a murine infection model. We observed that a single PDI treatment with this photo-
sensitizer/light combination significantly decreased the bacterial load in infected eyes by more than 90% at one h 
Figure 3. Clinical scores of mice treated by regimen I (chlorin e6 mediated PDI at 24 h post infection), 
recorded from hour 24 to day 3, grouped by the concentrations of chlorin e6 (Ce6) used in PDI. Means 
with standard deviations are shown. On day 2, clinical scores of 0.1% Ce6 group were significantly lower than 
the control group treated by 0% Ce6 (*P = 0.015). Clinical scores of 0% Ce6 group increased significantly from 
hour 24 to day 3 (*P = 0.009). Clinical scores of 0.01% Ce6 group increased significantly from hour 24 to day 2 
(*P = 0.026), and from hour 24 to day 3 (*P = 0.026).
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post PDI when Ce6 concentrations of 0.01% and 0.05% were utilized, indicating that this PDI procedure exhibits 
a bactericidal effect in the mouse cornea in vivo as it does in vitro41–44,50.
An interesting finding is that the highest killing efficiency of PDI by Ce6/red light was not achieved by the 
highest concentration of Ce6, i.e. 0.1%, but rather by lower Ce6 concentrations. Such a nonlinear correlation 
between concentration and photodynamic inactivation effect has been observed for many photosensitizers49, and 
is in line with our previous in vitro findings, indicating a dose-dependent bactericidal effect of PDI by Ce6 and red 
light against clinical P. aeruginosa isolates44. An explanation for this finding might be that an excess of the pho-
tosensitizer decreases the transmission of light required for efficient singlet oxygen generation49. Alternatively, 
higher Ce6 concentrations might induce the expression of export systems in P. aeruginosa resulting in a decreased 
concentration of the photosensitizer at/in the bacterial cell. However, the molecular mechanisms responsible for 
Figure 4. Representative corneal manifestations of mice treated by regimen I (chlorin e6 mediated PDI at 24 h 
post infection), in which PDI was mediated by (A,B,C) 0%, (D,E,F) 0.01%, (G,H,I) 0.05% and (J,K,L) 0.1% 
chlorin e6 (Ce6). Photos were taken (A,D,G,J) right before infection of P. aeruginosa (hour 0), (B,E,H,K) before 
PDI (hour 24), and (C,F,I,L) on day 3. (E) A characteristic infiltration ring of P. aeruginosa keratitis (clinical 
score 3). The corneal suppurative infiltration developed rapidly in all mice, but on day 3, it seemed to be milder 
in (L) the mouse treated by 0.1% Ce6 mediated PDI (clinical score 3) than the others (clinical score 4).
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decreased susceptibility of P. aeruginosa cells against PDI in presence of increased concentrations of Ce6 still need 
to be clarified.
The observations of equal to higher CFU values in the eyes of Ce6 treated mice at 72 h post infection (i.e. 48 h 
post PDI treatment) demonstrated on the other hand that a single PDI treatment was insufficient in resolving 
the infection in vivo. Especially the significant bacterial overgrowth induced by the 0.1% Ce6 PDI treatment at 
day 3 of regimen I is a matter of concern, although this bacterial overgrowth was not seen when Ce6 concentra-
tions ≤0.05% were utilized. This finding is supported by previous clinical case reports, indicating an increased 
risk of microbial infections as a complication that may be induced by corneal crosslinking29–38.
A solution to the possible bacterial overgrowth is crucial for the long-term safety of corneal PDI. A safe cor-
neal PDI can be applied repeatedly on the infected cornea until all bacteria are eradicated, which certainly maxi-
mizes the potency. To explore a safer PDI protocol, we carried out the experiments of regimen II and regimen III. 
Since P. aeruginosa overgrowth, the main problem, was on day 3, we only measured the CFU on day 3 in regimen 
II and regimen III.
In regimen II, we focused on 0.1% Ce6, as only this photosensitizer concentration induced a significant bac-
terial overgrowth in regimen I. When animals were treated once by PDI with 0.1% Ce6 at 12 h post infection, 
the clinical scores on day 3 did no longer differ from those seen in the eyes of the sham treated control group, 
suggesting that the risk of bacterial overgrowth might be decreased when PDI can be applied early in infection.
An inconsistency between the milder corneal symptom and higher bacterial load was found in the group 
treated by 0.1% Ce6 mediated PDI on day 3 of regimen I. A possible explanation might be that a higher propor-
tion of inflammatory cells (mainly neutrophils) recruited to the focus of corneal infection were killed by this 
PDI regimen, leading to a reduced inflammatory response at the later stage of infection, however, at the cost of 
bacterial overgrowth.
Figure 5. Log10CFU on day 3 of each mouse treated by regimen II (chlorin e6 mediated PDI at hour 12 
post infection) is displayed as a single dot in the scatter plot. Mean of Log10CFU of each group is shown as a 
bar. 0.1% chlorin e6 (Ce6) was used in PDI at hour 12, while 0% Ce6 was used in control group. There was no 
significant difference between the two groups.
Figure 6. Clinical scores of mice treated by regimen II (chlorin e6 mediated PDI at hour 12 post infection), 
recorded from hour 12 to day 3. Means with standard deviations are shown. 0.1% chlorin e6 (Ce6) was used 
in PDI at hour 12, while 0% Ce6 was used in control group. There was no significant difference between the two 
groups. Clinical scores of 0% Ce6 group increased significantly from hour 12 to day 2 (*P = 0.002), and from 
hour 12 to day 3 (*P = 0.002). Similarly, clinical scores of 0.1% Ce6 group increased significantly from hour 12 
to day 2 (*P = 0.002), and from hour 12 to day 3 (*P = 0.002).
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To test this hypothesis, we used the photosensitizer MB in combination with red light for PDI, which was 
reported to spare neutrophils at concentrations of about 100 μ M, and compared its effectivity to kill P. aeruginosa 
in the murine corneal scratch model with that of Ce6 mediated PDI49. Taking into account the insufficient dif-
fusion of this photosensitizer into the corneal stroma51, the molar concentration of 0.005% MB used in regimen 
III was 156 μ M, and thus slightly higher than the 100 μ M MB recommended in a previous in vitro study49, but 
just equivalent to 0.009% Ce6. Moreover, for the same amount of substance, the ROS generated from irradiated 
MB is just about 80% of that of Ce637. Clinical scores of the group treated by MB mediated PDI were not different 
from those of the control group, suggesting that the corneal infiltration was not markedly affected by this PDI 
treatment. Yet in regimen III, the group treated by MB mediated PDI showed a considerable tendency of bacterial 
overgrowth on day 3, compared with the control group (P = 0.060), while the group treated by 0.01% Ce6 medi-
ated PDI did not show such a bacterial overgrowth on day 3 (P = 0.333). This finding is supported by the previous 
Figure 7. Representative corneal manifestations of mice treated by regimen II (chlorin e6 mediated PDI at hour 
12 post infection), in which PDI was mediated by (A,B,C) 0%, (D,E,F) 0.1% chlorin e6 (Ce6). Photos were taken 
(A,D) right before infection of P. aeruginosa (hour 0), (B,E) before PDI (hour 12), and (C,F) on day 3. (B,E) At 
hour 12, corneal infiltrations were mild (clinical score 1), and the epithelial scratches made for infection of P. 
aeruginosa were still clearly seen. (C,F) The corneal infiltration was more severe in both mice on day 3 (clinical 
score 4).
Figure 8. Log10CFU on day 3 of each mouse treated by regimen III (methylene blue mediated PDI at 24 h 
post infection) is displayed as a single dot in the scatter plot. Mean of Log10CFU of each group is shown as a 
bar. 0.005% methylene blue (MB) was used in PDI at hour 24, while 0% MB was used in control group. There 
was no significant difference between the two groups.
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study that shows higher efficiency of Ce6 in comparison with MB in PDI of Gram-positive bacteria in vitro52. 
Since MB is not better than Ce6 in preventing bacterial overgrowth either, further study is required to compare 
more different photosensitizers.
Considering the potential of PDI as treatment option against infectious keratitis induced by MDR bacteria, 
additional experiments are warranted to better uncover the mechanism(s) that promote the bacterial regrowth 
after PDI treatment. The overall susceptibility of a pathogen to PDI may also have a profound effect on the bac-
terial regrowth after PDI. PDI of Gram-negative bacteria is more challenging than of Gram-positive bacteria, 
because Gram-negative bacteria are surrounded by a less permeable envelop consisting of an inner cytoplasmic 
membrane and an outer membrane, while Gram-positive bacteria are surrounded by a single cytoplasmic mem-
brane and a porous cell wall53. The overall outer membrane permeability of P. aeruginosa is even lower than that 
of most other Gram-negative bacteria, for example, 12 to 100-fold lower than that of Escherichia coli54. Thus, PDI 
might be particularly suited as therapy option against keratitis caused by MDR Gram-positive bacteria.
After all, Ce6, and additionally MB, are just two of the most basic photosensitizers applied for PDI. A large 
number of novel photosensitizers have been developed recently. In some in vitro studies, it has been suggested 
that polycationic conjugates of poly-L-lysine and Ce6 have higher efficiency for Gram-negative bacteria than free 
Ce642,55. Some photosensitizers even allow selective targeting and killing bacteria in the presence of mammal 
cells56–58. The development of the latter group of photosensitizers can not only improve the antibacterial killing 
potency, but also very likely to affect the safety of PDI. We are looking forward to further studies that address the 
in vivo efficiency of these novel substances against bacterial corneal infections.
In comparison with PDI, many other studies looked at different experimental approaches for treating P. aerug-
inosa keratitis. An animal study has compared the efficacy of antibiotics to treat P. aeruginosa keratitis59, and 
found that moxifloxacin, levofloxacin and ciprofloxacin were equally effective against the P. aeruginosa isolate 
tested. However, when keratitis is caused by a fluoroquinolone-resistant P. aeruginosa isolate, which are on the rise 
in many regions of the world, this class of antibiotics won’t be any longer a valid therapy option. Some other novel 
tools, such as bacteriophages and antimicrobial peptides (AMPs), are now under development, and each tool has 
its own risks and advantages. A recent study indicated for example the efficacy of bacteriophage KPP12 for the 
treatment of P. aeruginosa keratitis in vivo60. However, this study demonstrated that the bacteriophage failed to 
lyse about one third of the clinical P. aeruginosa strains tested, indicating that this therapy is likely to fail in a large 
number of cases. The AMP esculentin-1a(1–21)NH2, a frog skin-derived peptide, was also recently reported to 
significantly reduce the severity of infection in a murine P. aeruginosa keratitis model61, a three log10 reduction 
was achieved when the AMP was applied three times per day for four days post infection. However, the authors 
noted that the disease was still progressive even under this intensive regimen.
In summary, our current study has proven that Ce6 mediated PDI is able to cause about one log10 reduction 
of the MDR-PA cell pool in a murine keratitis model. However, the high numbers of bacterial cells seen at later 
stages post PDI suggest that consecutive rounds of PDI are required to reduce the amount of bacterial cells in 
infected eyes in a way that the host immune system can control the infection. The differences in bacterial growth 
observed after PDI with increasing photosensitizer concentration indicate furthermore that care needs to be 
taken to identify the optimal dose of photosensitizer to effectively decrease the bacterial burden without causing 
too many side effects that may interfere with bacterial clearance.
Materials and Methods
Materials. Agar plate of TrypticaseTM soy agar with 5% sheep blood (TSBA) (Becton Dickinson GmbH, 
Heidelberg, Germany). DifcoTM LB broth, Lennox (LB-L) (Becton, Dickinson and Company, Sparks, USA). 
Midazolam (Hameln Pharma Plus GmbH, Hameln, Germany). Fentanyl (Hameln Pharma Plus GmbH, Hameln, 
Germany). DomitorTM medetomidine hydrochloride (Orion Corporation, Espoo, Finnland). Naloxone hydro-
chloride (Inresa Arzneimtittel GmbH, Freiburg, Germany). Flumazenil (Inresa Arzneimtittel GmbH, Freiburg, 
Germany). AntisedanTM atipamezole hydrochloride (Orion Corporation, Espoo, Finnland). Sodium chloride 
(VWR International Ltd., Leuven, Belgium). Chlorin e6 gel (using hydroxypropyl methylcellulose as gel-base) 
Figure 9. Clinical scores of mice treated by regimen III (methylene blue mediated PDI at 24 h post 
infection), recorded from hour 24 to day 3. Means with standard deviations are shown. 0.005% methylene 
blue (MB) was used in PDI at hour 24, while 0% MB was used in control group. There was no significant 
difference between the two groups. Clinical scores of 0% MB group increased significantly from hour 24 to day 
3 (*P = 0.002). Clinical scores of 0.005% MB group increased significantly from hour 24 to day 2 (*P = 0.041).
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(by courtesy of APOCARE Pharma GmbH, Bielefeld, Germany). Methylene blue solution (Sigma-Aldrich, 
Steinheim, Germany). Phosphate-buffered saline (PBS) (Sigma-Aldrich, Steinheim, Germany).
Bacterial strain and culture conditions. The MDR P. aeruginosa strain PA54, isolated from human infec-
tion, was collected in 2009 at the Institute of Medical Microbiology and Hygiene, Saarland University Medical 
Center, Homburg, Germany. The resistance profile of PA54 was determined using the automated VITEK 2 system 
(bioMérieux GmbH, Nürtingen, Germany). PA54 was routinely cultivated overnight on TSBA at 37 °C.
Murine corneal scratch model. Mice. In preliminary experiments, we found that in mice younger than 
6 months, P. aeruginosa keratitis showed a trend of spontaneous resolution during one week. Therefore, we used 
eight-to-eleven month old female C57BL/6N mice, which were purchased from Janvier (Le Genest Saint Isle, 
France) and kept under specific pathogen-free conditions according to the regulations of German veterinary 
law. All experiments were conducted in accordance with the German legislation on protection of animals and 
the NIH Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, National 
Research Council, Washington, USA), and were approved by the local State Review Boards (Landesamt für 
Soziales, Gesundheit und Verbraucherschutz) of Saarland following the national guidelines for the ethical and 
humane treatment of animals.
Inoculum preparation. PA54 was grown overnight in LB-L at 37 °C, diluted in fresh medium in a ratio of 1:100, 
and incubated at 37 °C and 150 rpm shaking for 3 hours. Bacteria from the exponential growth phase were har-
vested by centrifugation, washed twice in PBS, resuspended in fresh LB-L to an optical density at 600 nm (OD600) 
of 10. The number of viable cells was determined by plating out serial dilutions on TSBA. CFU were counted after 
incubation overnight at 37 °C.
Infection. The time of infection of mice was deemed as hour 0 on day 0 of the experiment. Mice were nar-
cotized by intraperitoneal injection of 10 μ l/g anesthetic consisting of 5 μ g/ml Fentanyl, 0.5 mg/ml midazolam and 
0.05 mg/ml medetomidine hydrochloride in 0.9% sodium chloride solution. The natural tear flow was suppressed 
by dropping 10 μ l of a 0.6% acetyl-cysteine solution onto the cornea. Subsequently, mice were placed under a 
stereo-microscope, and three linear scratches (each ~2 mm) were made on the ocular surface of the left eye of 
each mouse by a 27 gauge syringe needle to expose the subepithelial stroma. 5 μ l of the PA54 suspension, corre-
sponding to 1 × 106 CFU, were pipetted onto the mechanically harmed cornea when mice were lateral recumbent. 
The bacterial solution was left on the eye for 20 minutes, and mice were subsequently awaked by injecting 10 μ l/g 
antidote consisting of 0.12 mg/ml naloxone hydrochloride, 0.05 mg/ml flumazenil and 0.25 mg/ml atipamezole 
hydrochloride in 0.9% sodium chloride solution.
Figure 10. Representative corneal manifestations of mice treated by regimen III (methylene blue mediated PDI 
at 24 h post infection), in which PDI was mediated by (A,B,C) 0%, (D,E,F) 0.005% methylene blue (MB). Photos 
were taken (A,D) right before infection of P. aeruginosa (hour 0), (B,E) before PDI (hour 24), and (C,F) on day 
3. (B,E) At hour 24, characteristic infiltration rings of P. aeruginosa keratitis were clearly seen (both clinical 
score 3). (C,F) The corneal infiltration was more severe in both mice on day 3 (clinical score 4).
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Grading of corneal infections. The corneal manifestation of the PA54 induced keratitis in the infected mouse eyes 
were examined daily under a stereomicroscope, and recorded as a clinical score using the following scale: Score 
0, entire cornea clear; score 1, < 50% cornea is semi-transparent (iris color behind the lesion can be identified); 
score 2, > 50% cornea is semi-transparent; score 3, < 50% cornea is opaque (iris color behind the lesion cannot be 
identified); score 4, > 50% cornea is opaque; score 5, corneal spontaneous perforation or phthisis bulbi. Corneal 
photos were taken under the stereomicroscope when mice were in anesthesia.
Bacterial load determinations. Enucleated mouse eyes were homogenized with a POLYTRON PT 1200 E 
Manual Disperser (Kinematica AG, Lucerne, Switzerland) in 1 ml LB-L, and serial dilutions of this homogenate 
plated on TSBA. After 24 h of incubation at 37 °C, CFU were counted.
PDI studies. All steps involving Ce6 were carried out in a dark room under weak yellow light exposure 
(λ = 596 nm) to avoid activation of the photosensitizer. Three regimens of PDI were tested (Fig. 1). In all reg-
imens, corneal epithelia of narcotized mice were removed by a hockey epithelium removal knife prior to PDI. 
The irradiation setting to activate Ce6 was identical in all regimens, with 6 minutes irradiation of red light 
(λ = 670 nm), equivalent to an energy dose of 24 J/cm2.
Regimen I. At 24 h post infection, corneal epithelia were removed from infected eyes, and about 50 μ l of a 0% 
(hydroxypropyl methylcellulose gel-base only), 0.01%, 0.05%, and 0.1% Ce6 gel dabbed onto the infected mouse 
cornea, respectively. Mice were then left in darkness for 30 minutes to allow the penetration of Ce6 into the cor-
neal tissues. Afterwards, gel residues were carefully removed with cotton swabs, and mouse corneas irradiated 
as indicated above. Mice were euthanized either 1 h post PDI or 48 h post PDI, the infected eyes enucleated and 
subsequently homogenized for CFU determinations.
Regimen II. Corneal epithelia were removed from infected eyes at 12 h post infection, and about 50 μ l of a 0% 
and 0.1% Ce6 gel dabbed onto the infected mouse cornea, respectively. The PDI treatment was carried out as 
described before. Mice were euthanized 60 h post PDI and handled as described above.
Regimen III. Corneal epithelia were removed from infected eyes at 24 h post infection, and about 20 μ l of a 
0.005% MB solution and PBS dropped onto the infected mouse cornea, respectively. The PDI treatment was car-
ried out as described before. Mice were euthanized 48 h post PDI, and handled as described above.
Statistical analysis. Statistical analysis was performed with IBM SPSS Statistics 22.0. Since bacterial growth 
data is a typical variable that follows the log-normal distribution62, after log transformation of the CFU values, 
independent samples t test following analysis of variance was used to compare Log10CFU. Mann-Whitney U test 
following Kruskal-Wallis test was used to compare clinical scores. P < 0.05 was considered statistically significant.
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